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http://dx.doi.org/10.1016/j.numecd.Abstract Background and aims: The Study on Lifestyle intervention and Impaired glucose tol-
erance Maastricht (SLIM), a randomized controlled trial, directed at diet and physical activity
in impaired glucose tolerant subjects was effective to improve glucose tolerance and prevent
type 2 diabetes. The aim of this study was to determine the effects of the SLIM lifestyle inter-
vention on the incidence and prevalence of the metabolic syndrome (MetS) during the active
intervention and four years thereafter.
Methods and results: MetS was diagnosed according to the NCEP ATP III criteria. At baseline,
66.4% of all participants (n Z 146, age 57  7 years, BMI 29.7  3.6, 51.3% female) fulfilled
the criteria for MetS. No significant difference in MetS prevalence was observed between
the intervention (63.9%) and control group (68.9%). At the end of active intervention (average
duration 4.2  2.0 years), prevalence of MetS was significantly lower in the intervention group
(52.6%, n Z 57) compared to the control group (74.6%, n Z 59) (p Z 0.014).
Furthermore, in participants without MetS at baseline, cumulative incidence of MetS was
18.2% in the intervention group at the end of active intervention, compared to 73.7% in the
control group (Log-rank test, pZ 0.011). Four years after stopping active intervention, the re-
duced incidence of MetS was maintained (Log-rank test, p Z 0.002).niversity, Department of Human Biology, PO Box 616, 6200 MD Maastricht, The Netherlands. Tel.: þ31
richtuniversity.nl (A.Th. den Boer).
qual contribution).
3 Elsevier B.V. All rights reserved.
2012.12.005
1148 A.Th. den Boer et al.Conclusion: In conclusion, a combined diet-and-exercise intervention to improve glucose tol-
erance, not only prevented type 2 diabetes, but also reduced the prevalence of MetS and pre-
vented MetS development, showing the long-term impact of lifestyle intervention on
cardiovascular risk reduction.
Clinical trial registration number: NCT 00381186 (www.clincialtrials.gov).
ª 2013 Elsevier B.V. All rights reserved.Introduction
The prevalence of metabolic syndrome (MetS) is rapidly
rising worldwide. MetS is a clustering of several metabolic
and cardiovascular risk factors, including abdominal obe-
sity, elevated fasting glucose, blood pressure, triglycerides,
and low HDL-cholesterol [1]. MetS increases the risk of both
cardiovascular disease and type 2 diabetes (T2D) [2e5].
Two large lifestyle intervention studies, the Finnish
Diabetes Prevention Study (DPS) and the US Diabetes Pre-
vention Program (DPP), designed to prevent type 2 diabetes
in impaired glucose tolerant (IGT) subjects through changes
in diet and physical activity, revealed a 58% risk reduction
in the development of type 2 diabetes [6,7], and a reduced
prevalence of MetS in the intervention group [8,9]. Weight
loss seems a major determinant of improvements in glucose
tolerance and the reduction of MetS prevalence [10e12],
whereas physical activity and dietary composition may
contribute independently [13].
In the Netherlands, a lifestyle intervention designed to
study the impact of diet and physical activity on glucose
tolerance in impaired glucose tolerant subjects has
been performed: the Study of Lifestyle intervention and
Impaired glucose tolerance Maastricht (SLIM). This study
has also shown a 58% reduction in diabetes risk after 3 year
and a 47% reduction at the end of intervention [14], despite
a relatively moderate weight reduction. The purpose of the
present study was to investigate the effect of the SLIM
study on the prevalence and prevention of metabolic syn-
drome, both during the active intervention and 4 years
thereafter.
Methods
Study design and population
The SLIM study is a randomized controlled intervention trial
conducted at the University of Maastricht, the Netherlands.
It was designed to study the effect of a combined dietary
and physical activity intervention on glucose tolerance in
IGT subjects [15,16]. Subject recruitment and design have
been extensively described previously [14,15,17]. Partici-
pants were recruited in two phases (1999 and 2001). Orig-
inally, study duration was 3 years, but this was extended
with 1e3 years (depending on recruitment) in 2002. At the
completion of the study in 2006, intervention duration was
3e6 years (on average 4.2 years). Four years later, a follow-
up measurement was performed. For inclusion at baseline,
mean 2 h glucose concentration of 2 screening oral
glucose tolerance tests (OGTT) had to be between 7.8 and
12.5 mmol/L with the first OGTT showing a concentration of7.8 mmol/L or more. Known diabetes and chronic illness
were main exclusion criteria (see Mensink et al. [15] for
more detailed eligibility criteria). In total, 147 participants
were included and randomized to the intervention and
control groups, with stratification for sex and mean 2 h
plasma glucose concentration. The Medical Ethical Review
Committee of Maastricht University approved the study
protocol and all participants gave their written informed
consent before the start of the study.
Lifestyle intervention
The intervention program consisted of a dietary and physical
activity part, as described previously [15]. Briefly, dietary
recommendations were based on the Dutch guidelines for
a healthy diet (Dutch Nutrition Council), and consisted of:
carbohydrate intake of at least 55% of total energy intake,
a reduction in fat intake of to 30e35% of total energy intake,
and increased intake of dietary fiber (>3 g/MJ/day) [15]. A
skilled dietician, trained in motivational interviewing, gave
personal dietary advice during a 1-h session every 3 months,
after consideration of a 3-day food record. At each visit, one
topic was discussed in detail and goals were set for the next
three months, as described in detail elsewhere [15]. Addi-
tionally, participants received individual advice on how to
increase physical activity to at least 30min a day for at least 5
days a week with the type of activity (i.e. walking, swim-
ming) depending on personal preferences [15]. Participation
in a free supervised, aerobic- and resistance-training pro-
gram for at least once a week was encouraged.
Control subjects received general information about
beneficial effects of a healthy diet and increased physical
activity, whereas no individual advice was provided.
Annual measurements
In the control and intervention group, anthropometry, glu-
cose tolerance, blood profile and blood pressure and aerobic
fitness were determined annually during the intervention
and at the follow-up. Body weight was measured with an
electronic scale to the nearest 0.1 kg. Height and waist cir-
cumference were measured to the nearest 0.5 cm, with the
subject in standing position. Waist was measured using an
anthropometric measuring tape, midway between the low-
est rib and the crest. Blood pressure was measured twice
with an Omron 705CP (Omron Healthcare GmbH, Hamburg,
Germany) in sitting position. An incremental exhaustive
exercise test was performed on an electronically braked bi-
cycle ergometer to determine maximal peak oxygen con-
sumption (VO2max). Changes in glucose tolerance were
studied using an OGTT. Blood samples were drawn after
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cose load (75 g glucose). Plasma glucose, HDL-cholesterol
and triglycerides were measured with standard enzymatic
techniques, automated on a Cobas Fara centrifugal analyzer.
LDL-cholesterol was estimated using the Friedewald equa-
tion [18].
MetS diagnosis
Patients were evaluated for the presence of MetS, ac-
cording to the modified Third Report of the US National
Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cho-
lesterol in Adults, ‘NCEP ATP III criteria’ (Table 2). These
criteria are defined as the presence of three or more of the
following criteria: large waist circumference; elevated
blood pressure, triglycerides, and fasting plasma glucose;
and decreased levels of HDL-cholesterol [1].
Statistical analysis
Groups were compared for prevalence of MetS (criteria)
using chi-square statistics and average clinical parameters
were compared using Student’s t-test. Wilcoxon’s non-
parametric test was used to compare the prevalence of
metabolic syndrome and its components within the groups
at different timepoints compared to baseline. Cumulative
incidence of the metabolic syndrome in the intervention
and control groups was compared using the Log-rank test.
Multivariate Cox regression analysis was performed to study
MetS development in the intervention and control groups
for all participants without MetS at baseline. Endpoint was
the first diagnosis of MetS or the last measurement, when
no MetS developed. Analysis was adjusted for gender and
age. Changes over time between groups were assessed
using ANOVA for repeated measures. Participants were
followed from study entry until withdrawal, death, emi-
gration, or the end of follow-up period. The level of sig-
nificance was set at 5% (two-tailed). Statistical Package for
the Social Sciences (SPSS) version 16.0 for Macintosh was
used to create a database and perform the statistical
analyses.
Results
Clinical characteristics of participants
At baseline, data for MetS diagnosis were available in 146 of
the 147 participants. Apart from age, baseline characteris-
tics were comparable between the intervention and control
groups. Despite randomization, age was higher in the con-
trol (58.2  7.2 years) compared to the intervention group
(55.1  6.5 years) (pZ 0.008). As previously reported [19],
after the first intervention year, there was a more pro-
nounced decrease in body weight, BMI, 2 h glucose and 2 h
free fatty acids (FFA) in the intervention group as compared
to the control group, whilst there was a more pronounced
increase in maximal aerobic capacity in the intervention
group (Table 1). At the end of the intervention (average
duration 4.2  2.0 years), the changes in body weight, 2 hFFA, blood pressure and aerobic capacity were significantly
different between the groups. At follow-up (average
4.5  0.5 years after end of active intervention), apart from
the change in aerobic capacity, these differences could no
longer be detected. Glucose, lipid and blood pressure low-
ering medication use increased over time in both groups,
without significant differences between the groups. All
participants using lipid-lowering medication were treated
with statins. At the end of the intervention, most partici-
pants treated with anti-hypertensive drugs used beta-
blockers (57%), angiotensin-2-blockers (34%), thiazide-
diuretics (26%), ACE inhibitors (23%) and calcium blockers
(13%). Percentages of participants on the different types of
anti-hypertensives were relatively constant over time, and
no differences between intervention and control groups
were observed (data not shown).
MetS prevalence
Overall, 66.4% of the participants fulfilled the criteria for
MetS according to the NCEP ATP III criteria. The prevalence
of MetS did not differ at baseline between the intervention
and control groups (Table 2). High blood pressure and large
waist circumference were most commonly present in our
IGT population at baseline, with percentages of 90.3 and
76.7 respectively, whereas 57.9% fulfilled the criteria for
low HDL-cholesterol, 40.4% for high fasting glucose and
30.3% for hypertriglyceridemia. No differences between the
intervention and control groups at baseline were observed
for the individual MetS components, except for high blood
pressure, which was more often present in control subjects
(Table 2). No age or gender differences were detected for
overall MetS prevalence (men 68.0% and women 64.8%).
As indicated in Table 2, no significant difference in MetS
prevalence was detected at year 1. Interestingly, at the end
of the intervention, significantly fewer participants in the
intervention group (52.6%) had MetS compared to the con-
trol group (74.6%) (p Z 0.014, Table 2). Because partici-
pants in the control group were significantly older than in
the intervention group, differences in MetS prevalence
were age adjusted. No effect of age on MetS incidence was
detected (data not shown).
Resolution and prevention of MetS
At the start of the SLIM intervention participants with
(n Z 97) and without (n Z 49) MetS joined the lifestyle
intervention. The effect of the intervention may differ for
people with or without MetS at baseline. Indeed, in par-
ticipants who already had MetS at baseline, no difference
between the intervention and control groups in prevalence
of MetS over time was observed. At the end of the inter-
vention, MetS was resolved in 25.0% in the control group
and 25.7% in the intervention group.
Interestingly, in participants who did not have MetS at
baseline, in the intervention group only 18.2% had MetS
(4 of 22) at the end of active intervention, compared to
73.7% in the control group (14 of 19). Cumulative incidence
of MetS over the intervention period was significantly lower
in this group without MetS at baseline in intervention sub-
jects as compared to control subjects (Fig. 1, Log-rank test:
1 Development of characteristics of the SLIM population during the lifestyle intervention.
eter Baseline Year1 End of intervention (year 3e6) Follow-up (4.5 years after
intervention)
Control Intervention Control Intervention p-valuea Control Intervention p-valuea Control Intervention p-valuea
Mean St.dev. Mean St.dev. Mean St.dev. Mean St.dev. Time*
Group
Mean St.dev. Mean St.dev. Time*
Group
Mean St.dev. Mean St.dev. Time*
Group
74 72 67 63 59 57 28 32
male/female 37/37 34/38 36/31 35/28 32/27 31/26 14/14 16/16
(years) 58.2 7.2 55.1 6.5 59.3 7.1 56.1 6.7 63.1 7.2 59.4 6.8 67.7 7.5 65.9 5.8
ht (kg) 84.3 12.2 86.2 12.8 84.2 11.4 84.1 13.1 0.005 84.5 12.5 85.8 13.3 0.046 85.1 10.8 86.7 13.4 0.364
(kg/m2) 29.8 3.7 29.5 3.5 29.6 3.5 28.6 3.5 0.006 29.7 3.8 29.1 3.5 0.050 30.2 3.7 28.9 3.7 0.388
t (cm) 103.7 9.7 102.9 10.2 101.9 9.6 99.9 11.2 0.117 103.6 8.5 101.4 11.0 0.123 103.5 8.3 103.0 10.5 0.864
ng glucose (mmol/L) 5.9 0.7 6.1 0.9 5.9 0.6 6.0 0.9 0.112 6.4 0.8 6.2 0.9 0.088 6.2 0.7 6.2 1.1 0.755
ucose (mmol/L) 8.8 2.1 8.9 2.1 8.7 2.2 8.2 2.0 0.009 9.7 2.6 9.0 2.5 0.073 10.0 2.7 9.4 2.9 0.735
c (%) 6.0 0.5 5.9 0.5 5.7 0.4 5.7 0.4 0.359 6.2 0.7 6.1 0.4 0.595 5.9 0.4 6.0 0.5 0.833
iastolic (mmHg) 88.9 8.0 89.0 9.2 88.4 8.0 87.7 7.3 0.292 85.4 8.8 82.6 6.1 0.020 78.8 9.5 78.0 12.2 0.291
stolic (mmHg) 144.9 14.5 141.6 17.0 140.4 16.0 138.3 14.7 0.828 139.7 14.8 134.4 13.1 0.625 132.8 16.1 131.0 23.2 0.975
cerides (mmol/L) 1.43 0.78 1.53 1.19 1.59 1.17 1.53 1.42 0.275 1.49 1.05 1.35 0.81 0.355 1.35 0.67 1.28 0.54 0.563
(mmol/L) 1.12 0.28 1.14 0.31 1.10 0.30 1.14 0.30 0.847 1.19 0.28 1.27 0.36 0.673 1.39 0.35 1.36 0.31 0.880
ated LDLb (mmol/L) 3.52 0.75 3.33 0.95 3.56 0.84 3.30 0.89 0.460 3.59 0.89 3.43 0.78 0.709 3.80 0.98 4.39 1.03 0.005
l
olesterol
(mmol/L) 5.28 0.85 5.17 0.83 5.39 0.84 5.14 0.82 0.282 5.46 0.94 5.32 0.79 0.666 5.57 1.45 6.36 1.12 0.003
ng FFA (mmol/L) 557 178 599 211 485 136 473 152 0.103 445 132 442 132 0.254 523 166 497 174 0.965
A (mmol/L) 103 40 115 72 87 33 81 38 0.015 92 38 85 64 0.010 79 34 79 49 0.659
ax (L/min) 2.06 0.57 2.18 0.59 2.14 0.60 2.38 0.63 0.036 2.02 0.63 2.34 0.61 0.003 1.99 0.58 2.11 0.51 0.012
ose-
ering
dication
% (yes/total) 0.0% (0/74) 0.0% (0/72) 0.0% (0/67) 0.0% (0/63) 8.5% (5/59) 7.3% (4/55) 17.9% (5/28) 9.1% (3/33)
pertensive
dication
% (yes/total) 23.0% (17/74) 30.6% (22/72) 25.4% (17/67) 33.3% (21/63) 35.1% (20/57) 50.0% (28/56) 53.6% (15/28) 56.3% (18/32)
-lowering
dication
% (yes/total) 8.1% (6/74) 8.3% (6/72) 11.9 (8/67) 6.3% (4/63) 19.3% (11/57) 17.9% (10/56) 53.6% (15/28) 34.4% (11/32)
peated measures ANOVA.
L-cholesteol levels were estimated using the Friedewald equation, deducting both HDL-cholesterol and triglycerides from total cholesterol.Table
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Prevention of the metabolic syndrome in IGT subjects in the SLIM lifestyle intervention 1151p Z 0.003). In a Cox proportional hazards analysis, the
intervention yielded a reduction of 72.5% in incidence of
metabolic syndrome compared to the control group
(p Z 0.011, hazard ratio (HR) 0.375, 95% CI, 0.176e0.800).
Adjustment for age and gender resulted in an HR of 0.297,
95% CI 0.133e0.660 (pZ 0.003). Moreover, all intervention
participants who developed MetS had the minimum of 3
positive MetS criteria, whereas the average was 3.9  0.9
positive criteria in the control group (unpaired t-test,
p Z 0.003) at the end of active intervention.
Interestingly, although the MetS prevalence was not
significantly different between the intervention group and
the control group at the follow-up, all control participants
without MetS at baseline had developed MetS during the
intervention or follow-up, whereas 45.5% of the inter-
vention subjects remained free of MetS at all times,
showing a preventive effect of the SLIM lifestyle inter-
vention in the long term (Fig. 1, Log-rank test, pZ 0.002).
Dropouts
As reported previously, during active intervention, no sig-
nificant differences in number of dropouts between the
intervention (n Z 16) and control groups (n Z 16) were
present. At baseline, adherent subjects had lower 2 h glu-
cose levels, a lower BMI and higher VO2 max and were
higher educated [14].
Sixty participants attended the follow-up measurements
4.5  0.5 years after the last measurement in the active
intervention. Main reasons for dropout at the follow-up
measurement were medical (22%), no time or motivation
(each 17%), and age (11%). One participant died (cause of
death unknown). Non-fatal cardiovascular events took
place during the follow-up period (i.e. atrial fibrillation and
heart infarction), 4 in the control and 5 in the intervention
group. The follow-up participants were 53e79 years old
(mean age 66.8  6.6 years), a comparable number of
participants from the intervention (n Z 32) and control
group (nZ 28) were measured and half of the participantsFigure 1 MetS free survival in subjects without MetS at
baseline. MetS was determined in subjects without MetS
at baseline, during active intervention (year 3e6) and at
the follow-up measurement. Percentage MetS free survival in
the intervention (closed circles) and control group (open
circles).
1152 A.Th. den Boer et al.were female. In line with results at the end of active
intervention, adherent subjects at follow-up had lower
baseline 2 h glucose values (8.42  1.82 mmol/L versus
9.17 2.19 mmol/L in dropouts, pZ 0.032) and were higher
educated (Chi-square test, p Z 0.012) compared to drop-
outs. MetS prevalence at baseline did not differ between
adherent subjects and dropouts, neither at the end of active
intervention (Chi-square test, p Z 0.447) nor at follow-up
(Chi-square test, p Z 0.759). No differences in baseline
MetS prevalence in the intervention or control group
were observed between adherent subjects and dropouts.Discussion
Our data show that the combined diet-and-exercise SLIM
intervention program not only prevented type 2 diabetes
(47% reduction) [14], but also reduced MetS prevalence at
the end of active intervention and prevented development
of new MetS cases in the intervention group. This preven-
tive effect on MetS incidence was sustained in intervention
participants until 4.5 years after stopping the active
intervention.
Our data are consistent with results from the DPP life-
style intervention, which showed prevention of new MetS
cases three years after start of the intervention [8]. The
preventive effect of the SLIM intervention on MetS inci-
dence was present at the end of active intervention, but not
yet detected after one year, whereas changes in weight,
glucose tolerance and aerobic fitness were largest in the
first year of intervention. Reduction of cardiovascular risk
factors as clustered in the MetS through lifestyle inter-
vention may only become apparent after several years.
Although new cases of MetS were prevented in the SLIM
intervention group, resolution of existing MetS was not
different in the intervention and control groups. In contrast
to our findings, existing MetS was resolved in the inter-
vention group in the DPS [9] and DPP [8]. In both studies,
the lower prevalence of MetS in the intervention group was
strongly related to a reduction in waist circumference,
which is likely to correspond to the pronounced weight loss
achieved. In the SLIM lifestyle intervention waist circum-
ference (2.9  4.6 cm) and weight (2.4  3.6 kg)
reduction in the intervention group in the first year was
limited compared to the DPS (4.2  5.1 kg) [7] and DPP
(5.6 kg) [6]. This may explain the difference in active
resolution of MetS in participants who already had the
syndrome at baseline. In line, several studies demonstrated
that weight loss was associated with a decrease in the
number of MetS components [20,21].
Average MetS prevalence in IGT participants of the SLIM
study was 66.4% at baseline. In the DPS, 74% of IGT subjects
had MetS at baseline, whereas the DPP reported 53%. The
lower MetS prevalence in the DPP could be due to the
younger age of participants. In the DPS, the fasting glucose
criterion for MetS was considered positive at 5.6 mmol/L, in
contrast to 6.1 mmol/L as used in this study and the DPP.
The American Diabetes Association recently redefined
prediabetes as fasting plasma glucose greater than
5.6 mmol/L [22]. Lowering the cut-off to 5.6 mmol/L would
result in a MetS prevalence of 76.7% in the SLIM population,
which is comparable to the prevalence in the DPS.A limitation of our study is the relatively high number of
dropouts during active intervention and during follow-up.
These dropout rates were higher than reported in the DPS
[7,23], which had a similar set-up as the SLIM study. Nev-
ertheless, our dropout rate during intervention was similar
to other studies, like the DREAM trial [24]. Explanations for
the different dropout rates in the SLIM and DPS intervention
may be the recruitment of participants. Because SLIM
participants were recruited from the general population,
and not via advertisements as in the DPS [25], they may
have had less internal motivation to participate in the
study. In addition, because weight loss was limited in the
SLIM study, participants may have been less satisfied with
the results of intervention.
During active intervention and follow-up, the highest
dropout occurred in participants with the worst metabolic
profile. As also previously reported these subjects also had
a low socio-economic status [14]. This is in line with other
data in literature suggesting that participants at higher risk
are more likely to dropout [26,27]. This selective dropout
stresses the difficulty to reach and sustain changes in this
vulnerable group and the need for programs tailored to-
wards these vulnerable groups to achieve and maintain
positive lifestyle changes.
In conclusion, a combined diet-and-exercise lifestyle
intervention to improve glucose tolerance, not only pre-
vented type 2 diabetes, but also reduced the prevalence of
MetS in the intervention group, and thereby could con-
tribute to cardiovascular risk reduction.Funding source
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